Insider Spends US$67k Buying More Shares In AngioDynamics
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript
AngioDynamics Third Quarter 2024 Earnings: Misses Expectations
Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential
Q3 2024 AngioDynamics Inc Earnings Call
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
AngioDynamics Inc (ANGO) Posts Q3 Fiscal 2024 Results: A Mixed Performance Amidst Asset Divestiture
Options Volatility and Implied Earnings Moves Today, April 04, 2024
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
AngioDynamics (ANGO) Settles Patent Litigations With BD
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.